Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-Line Helicobacter pylori Eradication: A Randomized Controlled Trial

Background. A new agent, potassium-competitive acid blocker vonoprazan (VPZ) has potent acid-inhibitory effects and may offer advantages over conventional H. pylori eradication therapies. We aimed to compare the eradication rate between VPZ-based treatment and PPI-based one. Methods. This randomized...

Descripción completa

Detalles Bibliográficos
Autores principales: Maruyama, Masafumi, Tanaka, Naoki, Kubota, Daisuke, Miyajima, Masayuki, Kimura, Takefumi, Tokutake, Koujiro, Imai, Ryujiro, Fujisawa, Toru, Mori, Hiromitsu, Matsuda, Yoshiaki, Wada, Shuichi, Horiuchi, Akira, Kiyosawa, Kendo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2017
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5350398/
https://www.ncbi.nlm.nih.gov/pubmed/28349044
http://dx.doi.org/10.1155/2017/4385161

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5350398/
https://www.ncbi.nlm.nih.gov/pubmed/28349044
http://dx.doi.org/10.1155/2017/4385161

Ejemplares similares